Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics

Fundamental and Clinical Pharmacology

Volumn 13, Issue 2, 1999, Pages 232-236

  Becquemont, Laurent ^a   Funck Brentano, Christian ^a   Jaillon, Patrice ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cytochrome P450; Drug interaction; Mibefradil; Pravastatin

Indexed keywords

CYTOCHROME P450 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIBEFRADIL; PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033278518     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1999.tb00344.x     Document Type: Article

References (14)

1. Mibefradil: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris
2. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors
6. Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
7. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
8. Accumulation of lovastatin but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses
9. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin
10. What lessons can be learnt from withdrawal of mibefradil from the market?
11. In vitro metabolism of simvastatin in humans (SBT) identification of metabolizing enzymes and effects of the drug on hepatic P450s
12. Clinical pharmacokinetics of pravastatin
13. Rhabdomyolysis due to interaction of simvastatin with mibefradil
14. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes